Medicare Payment Policy For Dialysis Drugs Seeks To Promote Innovation, Restrain Costs

More new dialysis drugs would be eligible for Medicare add-on payments under proposed rule, but payment amounts would be lower.

shelves

The US Centers for Medicare and Medicaid Services is proposing to broaden the pool of new prescription drugs for end-stage renal disease that are eligible for add-on reimbursement payments from Medicare.

The new policy is part of a proposed rule updating the Medicare end-stage renal disease (ESRD) prospective payment system for 2019

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Medicare

Medicare Negotiation Does Not Violate Due Process, Appeals Court Rules, Other Suits At Risk

 
• By 

Decision in AstraZeneca’s lawsuit against the Health and Human Services Department is a precedent-setting victory for the government and a blow to manufacturer efforts to block the price negotiation program.

If CMS Takes Over 340B, Will Government Allow Rebate Model Changes?

 
• By 

Manufacturers have supported the proposed shift in oversight authority, which could create a more pharma-friendly environment in the drug discount program, but uncertainty remains.

Stand-Alone PDP Market Lives to Fight Another Day, Enrollment Data Shows

 
• By 

No mass exodus was seen from stand-alone prescription drug plans to Medicare Advantage drug plans between 2024 and 2025, according to one actuary.

Proposed HHS Budget Would Eliminate Medicare Negotiation Program Start-Up Funding

 
• By 

The preliminary budget document supports legislation clawing back funds appropriated for the program.

More from Government Payers